How ICER’s Assessment of New Migraine Treatments Ignores Patient Needs

A recent assessment by the Institute for Clinical and Economic Review (ICER) of a new class of migraine treatments – calcitonin gene-related peptide (CGRP) inhibitors – fails to incorporate improvements to patients’ productivity in its price recommendations despite evidence that the impact of migraines on patient productivity is significant. ICER’s biased assessment also goes against best practices recommended by experts in the field of cost-effectiveness analysis and highlights how their approach skews results to put payer needs over patients. Download the case study to learn more.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.